Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06678867
PHASE2

The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours

Sponsor: University College, London

View on ClinicalTrials.gov

Summary

The aim of the study is to examine the safety and feasibility of using 5-ALA in children who have MRI scans showing an aggressive looking brain tumour. It will also study if 5-ALA can help the surgeon achieve maximal tumour removal and discriminate between normal brain tissue and tumour. Patients will be between 3-18 years (inclusive) and all patients will receive 5-ALA 3-6 hours prior to resection surgery.

Official title: A Phase II Multicentre Trial for the Use of 5-ALA Paediatric Patients With High Grade Brain Tumours

Key Details

Gender

All

Age Range

3 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-03-25

Completion Date

2026-12-30

Last Updated

2025-03-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

5-ALA (Gliolan)

Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery

Locations (1)

Nottingham Children's Hospital

Nottingham, United Kingdom